Table 1.
Clinicopathologic characteristics of 58 patients with APL receiving different maintenance regimens
| Characteristic | ATRA+As2O3 maintenance (N=30) | ATRA+chemotherapy maintenance (N=28) | P-value |
|---|---|---|---|
| Age (years), median (range) | 41 (15–64) | 43.5 (17–70) | 0.4933 |
| 15–39, n (%) | 12 (40.0) | 12 (42.9) | 0.557 |
| 40–60, n (%) | 16 (53.3) | 12 (42.9) | |
| >60, n (%) | 2 (6.7) | 4 (14.2) | |
| Sex | |||
| Male, n (%) | 12 (40.0) | 19 (67.9) | 0.034 |
| Female, n (%) | 18 (60.0) | 9 (32.1) | |
| WBC count (×109/L), median (range) | 1.49 (0.52–6.83) | 2.14 (0.85–8.7) | 0.0165 |
| <5, n (%) | 28 (93.3) | 20 (71.4) | 0.027 |
| 5–10, n (%) | 2 (6.7) | 8 (28.6) | |
| Platelet count, ×109/L, median (range) | 20.5 (2–176) | 28.5 (3–135) | 0.4884 |
| ≤40, n (%) | 24 (80.0) | 17 (60.7) | 0.107 |
| >40, n (%) | 6 (20.0) | 11 (39.3) | |
| Hemoglobin (g/L), median (range) | 81 (39–144) | 90.5 (44–149) | 0.1435 |
| Induction regimens | |||
| ATRA+As2O3+IDA, n (%) | 8 (26.7) | 3 (10.7) | 0.121 |
| ATRA+IDA, n (%) | 22 (73.3) | 25 (89.3) |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.